Drug maker Hospira has confirmed that the company is once again producing the anesthetic Propofol, following a voluntarily recall of the anesthetic in summer 2010, according to a Chicago Tribune report.
Hospira said it has been working with Food and Drug Administration regulators on its quality issues, which have negatively impacted the company's sales in the last year.
According to the report, Hospira reported a stronger-than-expected 6 percent profit increase in the first quarter. Net income rose to $149.9 million, or 88 cents a share, from $141.7 million, or 84 cents a share, a year earlier.
Read the Chicago Tribune report on Hospira.
Related Articles on Drug Shortages:
American Society of Anesthesiologists Conducts Survey on Drug Shortages
South Dakota Hospitals Search for Ways to Weather Drug Shortage
Drug Shortages Cost Providers $200M Annually, Endanger Patient Safety
Hospira said it has been working with Food and Drug Administration regulators on its quality issues, which have negatively impacted the company's sales in the last year.
According to the report, Hospira reported a stronger-than-expected 6 percent profit increase in the first quarter. Net income rose to $149.9 million, or 88 cents a share, from $141.7 million, or 84 cents a share, a year earlier.
Read the Chicago Tribune report on Hospira.
Related Articles on Drug Shortages:
American Society of Anesthesiologists Conducts Survey on Drug Shortages
South Dakota Hospitals Search for Ways to Weather Drug Shortage
Drug Shortages Cost Providers $200M Annually, Endanger Patient Safety